Gene Interactions: Developing a taxonomy for colorectal cancer
Colorectal cancer is challenging to treat because different patients have widely varying symptoms and the cancers display a broad range of molecular characteristics (Guinney et al., 2015). What can researchers and clinicians do to overcome these obstacles? First, it is necessary to understand the biological properties that make each type of colorectal cancer different, and to establish a precise molecular classification for the different subtypes based on these differences. This will help researchers to develop effective drug interventions. In the past decade, many diseases have been classified based on their transcriptome. However, this ignores the fact that levels of gene expression can vary widely in living patients (Wang et al., 2019).
Now, in eLife, Zhenqiang Sun, Xinwei Han and colleagues at the First Affiliated Hospital of Zhengzhou University – including with Zaoqu Liu as first author – report how they have developed a taxonomy for colorectal cancers based on the interactions between genes rather than on the levels of gene expression (Liu et al., 2022). This approach analyzes networks of gene interactions, which tend to be conserved in healthy samples, but are perturbed in cancer. This makes it possible to characterize the different types of tumors based on how their gene interaction networks are perturbed.
First, the researchers. used a dataset including tumors and healthy samples to generate a large-scale network that had genes as the nodes of the network, and the interactions between genes as the edges. Next, for both healthy and cancerous samples, they quantified the level of perturbation by measuring how the interactions between each pair of genes in the network had changed.
This analysis showed that the perturbations were much stronger in the tumors. Moreover, using a computational approach called clustering analysis, Liu et al. were able to establish six subtypes of colorectal cancers, which they called gene interaction-perturbation network subtypes (or GINS for short; Figure 1). Comparing this new taxonomy with previously published classifications of colorectal cancers revealed that there are notable differences between GINS and subtypes from other taxonomies (Figure 1). Liu et al. were able to confirm the stability and reproducibility of their proposed classification by validating it in independent datasets, which suggests that this taxonomy will be extremely useful for clinical applications.
A good molecular classification needs to convey clear biological interpretations of the underlying data, as this will help lay the ground for trials and treatments aimed at specific subtypes (Lin et al., 2021; Ten Hoorn et al., 2022; Singh et al., 2021). Along these lines, Liu et al. report distinguishing features for each of the six subtypes they have identified. For example, GINS1 is a proliferative subtype, whereas GINS2 is a stromal-rich subtype; Figure 1 has details on the other four subtypes.
Looking forward, the new taxonomy will need to be validated by further studies in different populations. Additionally, the classification could be improved by integrating multi-omics data – such as transcriptomic data and proteomic data – into the network. In recent years, the HuRI and BioPlex initiatives have provided comprehensive human interactomes at the proteome level, improving our understanding of genotype-phenotype relationships (Luck et al., 2020; Huttlin et al., 2021). These could be used to make the new perturbation network more robust. Finally, it might also be possible to apply the new network to other challenges, for example, to identify new therapeutic agents for colorectal cancer through network-based approaches (Fang et al., 2021).
The work of Liu et al. is another example of the use of network-based approaches to classify cancer subtypes, such as the recent molecular taxonomy developed for meningioma (Nassiri et al., 2021). The results present and validate a new classification system for colorectal cancer, providing more insights into the heterogeneity of the disease, and facilitating both translational research and personalized approaches to treatment.
References
-
The consensus molecular subtypes of colorectal cancerNature Medicine 21:1350–1356.https://doi.org/10.1038/nm.3967
-
Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta-analysisJournal of the National Cancer Institute 114:503–516.https://doi.org/10.1093/jnci/djab106
Article and author information
Author details
Publication history
Copyright
© 2022, Fang et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 460
- views
-
- 38
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
- Genetics and Genomics
The expression of eukaryotic genes relies on the precise 3'-terminal cleavage and polyadenylation of newly synthesized pre-mRNA transcripts. Defects in these processes have been associated with various diseases, including cancer. While cancer-focused sequencing studies have identified numerous driver mutations in protein-coding sequences, noncoding drivers – particularly those affecting the cis-elements required for pre-mRNA cleavage and polyadenylation – have received less attention. Here, we systematically analysed somatic mutations affecting 3'UTR polyadenylation signals in human cancers using the Pan-Cancer Analysis of Whole Genomes (PCAWG) dataset. We found a striking enrichment of cancer-specific somatic mutations that disrupt strong and evolutionarily conserved cleavage and polyadenylation signals within tumour suppressor genes. Further bioinformatics and experimental analyses conducted as a part of our study suggest that these mutations have a profound capacity to downregulate the expression of tumour suppressor genes. Thus, this work uncovers a novel class of noncoding somatic mutations with significant potential to drive cancer progression.
-
- Cancer Biology
- Immunology and Inflammation
The immunosuppressive microenvironment in pancreatic ductal adenocarcinoma (PDAC) prevents tumor control and strategies to restore anti-cancer immunity (i.e. by increasing CD8 T-cell activity) have had limited success. Here, we demonstrate how inducing localized physical damage using ionizing radiation (IR) unmasks the benefit of immunotherapy by increasing tissue-resident natural killer (trNK) cells that support CD8 T activity. Our data confirms that targeting mouse orthotopic PDAC tumors with IR together with CCR5 inhibition and PD1 blockade reduces E-cadherin positive tumor cells by recruiting a hypoactive NKG2D-ve NK population, phenotypically reminiscent of trNK cells, that supports CD8 T-cell involvement. We show an equivalent population in human single-cell RNA sequencing (scRNA-seq) PDAC cohorts that represents immunomodulatory trNK cells that could similarly support CD8 T-cell levels in a cDC1-dependent manner. Importantly, a trNK signature associates with survival in PDAC and other solid malignancies revealing a potential beneficial role for trNK in improving adaptive anti-tumor responses and supporting CCR5 inhibitor (CCR5i)/αPD1 and IR-induced damage as a novel therapeutic approach.